SOM BIOTECH
 

SOM BIOTECH, The drug repositioning company

SOM  Biotech (SOM)  is a company established at the Barcelona Science Park with the mission to discover and develop new indications of already known drugs (repositioning) through a profitable private company committed to its shareholders, employees and society. Repositioned drug access implies discovering, pre-clinical validation, patenting and licensing already known drugs for their commercial use in unknown medical uses.  Our propietary virtual screening  platform is based on an in-silico computerized approach and the drug development is driven by a dedicated team of experts and strategy advisors.

 

Hot News

SOM0226 presented at the XIIIth International Symposium on Amyloidosis

May 6-10, 2012

SOM0226, a reprofiled drug for the treatment of TTR amyloidosis, has been presented at the XIIIth International Symposium on Amyloidosis in Groningen, The Netherlands. The product has been recognized as one of the most promising in-coming therapies by the scientific expert community in the field.
 
SOM Biotech granted SME status by the EMA

Apr 17th, 2012

SOM Biotech has been granted SME status as micro-sized enterprise in research and development by the European Medicine Agency (EMA). The main incentives include: fee reductions in regulatory procedures and scientific advice, administrative assistance, and more economical access to various services provided by EMA.
 
SOM Biotech starts collaborations with Aagami Inc.

Mar 15th, 2012

SOM Biotech reaches an agreement with Aagami Inc. to start collaborations with Indian pharmaceutical companies interested in drug reprofiling.
 

BIOINCUBADORA

innova31

logo_biocat_rgb

Catalonia BIO

asebio

Genoma España

NEWS